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INTRODUCTION
The Human Immunodeficiency Virus (HIV) has earned
an indelible place in the history of man. First discovered
and described in 19811,2 It is rapidly becoming the
most significance pandemic in history of diseases of
man. The only other pandemic that caused more deaths
than HIV-AIDS to date is Yersinia pestis, the Black Death
which led to over 70 million deaths3. Next to cancer,
HIV is currently the most feared disease in modern
times, affecting over 30 million people worldwide4.
Sub-saharan Africa bears the largest burden of the
pandemic, with South-Africa and Nigeria being the
worst affected countries in the world4. The disease is
presently incurable despite the huge sums of money
that has been devoted to rigorous and cutting edge
research. The virus, which infects every age group,
causes an acute – chronic and eventually fatal illness.
Factors complicating efforts towards controlling the
disease include the huge stigma associated with the
illness. Stigma results in many infected individuals hiding
their status by rejecting voluntary screening and delaying
or even rejecting treatment. This continues to promote
the spread of  the virus.
The advent of Highly Active Antiretroviral Therapy
(HAART) has significantly transformed the natural
history of  the disease. Today millions are living normal
lives with complete suppression of the virus by
powerful combination therapies known by the
abbreviation HAART. Highly Active Antiretroviral
Therapy (HAART) has been shown to effectively
reverse the effects of the disease and reduce the viral
load to undetectable levels5-8. Well coordinated efforts
are ongoing to further expand the drug options for
HAART and reduce the side-effects of  the drugs. There
are also promising efforts towards finding easier drug
regimens and cheaper options to enable more people
living with the virus have access to the drugs and be
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SUMMARY
Timothy Ray Brown is widely referred to as the first HIV patient to be
cured of the disease. He received a CCR5 deficient bone marrow
transplant as a treatment for Acute Myeloid Leukemia, with HAART
controlled HIV-1 infection at the background. Seven years after the
transplant, and discontinuation of  HAART, he has been free of  the virus.
Several tests conducted to detect elements of  the virus have turned up
negative. This has suggest renewed and more determined interest in
finding a lasting cure for HIV-AIDS and has given birth to the era of
HIV cure research.
able to adhere to therapy. However, the ultimate goal
remains developing a cure for the disease.
Hope for a cure was very low and the focus for a
long time was, and still is, optimizing HAART regimens;
then a totally unforeseen phenomenon occurred. This
phenomenon was a European patient who today is
known as the Berlin patient.
Timothy Ray Brown, the Berlin Patient
Functional cure for HIV AIDS has been achieved in
patients who received experimental therapies that left
them free of the virus for many years without Anti-
retroviral drugs. Two such patients have been
mentioned in the history HIV cure research. Similar
cases of cure have come to be colloquially known as
“Berlin patient.” In 1998 the first Berlin patient was
described but the identity of the patient was not
revealed in the report and since then not much has
been said or known about him9. In 2008, the well
known case of Timothy Brown was reported in the
New England Journal of Medicine10.
Timothy Ray Brown had acute myeloid leukemia and
HIV for over ten years before he underwent the
miracle procedure. He was on HAART (600mg of
efavirenz, 200mg of emtricitabine, and 300mg of
tenofovir daily) with adequate HIV-1 control. When
he suffered a relapse in his leukemia, his doctor and
managing team decided to give him a bone marrow
transplant. In 2002 he received an allogenic bone
marrow transplant from a patient who was
homozygous for a 32bp deletion in the CCR5 allele
known to result in resistance to HIV invasion of CD4
cells10. Since the transplant he has remained free of
HIV-1 despite not being on HAART for over seven
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years. He is currently considered as the first case of
HIV-1 to be cured of  the disease. The transplant cured
his leukemia and eliminated the HIV.
HIV Cure
The case of Timothy Ray brown has generated new
hope in finding a lasting cure for the disease. This hope
has resulted in workshops, conferences, and seminars
on research with potential for cure of  HIV, an idea
that was once considered impossible or too distant
for any serious consideration. Now the possibility of
curing the disease is before us and there are some
immediate challenges. There is the need to start putting
in place the required terminologies in this emerging
era of HIV cure research.
New definitions are already being considered and
proposed, some of which include:
Stage 0 HIV: a new case definition of  the disease
that considers the presence of viral elements before
immunologic seroconversion, usually within weeks to
six months of primary infection11. This case definition
may become very relevant based on emerging evidence
indicating that one of the factors associated with cure
or prolonged viral control is early commencement of
antiretroviral therapy.
HIV suppression therapy: patient who is on effective
HAART and meeting the criteria for viral control,
below detectable limits. This is currently a major
objective of  HIV therapy.
Post Treatment Controllers (PTCs): Subjects who
are initiated on HAART within 10 weeks of a primary
HIV infection and are able to achieve a steady state of
therapy with a viral load below 400 RNA copies/ml
over a period of  at least 24 months. They were first
reported by Hocqueloux et al in 2010 as a special
population of patients12.
Functional cure: HAART treated Patient who
remains controlled after discontinuing therapy for
prolonged periods, usually over 6 months of being
HAART free. This is the lack of detectable viremia in
the absence of HAART despite presence of
replication-competent virus and normal or near
normal immune functions13.
Sterilizing cure: HAART treated patient without any
detectable element of the virus in his or her cells after
10 years of  discontinuing therapy. This is as a result of
the eradication of all replication-competent viruses13.
These are some of  the evolving terminologies that
will need further refinements in this new era of HIV
cure research; they come along with a lot of excitement
and hope. What is certain today is that HIV research
has moved closer to finding a cure like never imagined
in recent years. It is also becoming clearer that early
initiation of HAART within 10 weeks of primary HIV
infection may be the foundation for achieving
functional cure, the ‘Hit fast, Hit hard’ principle14. The
challenge of getting infected subjects early enough for
commencement of therapy will require a lot of effort
by HIV researchers if the goal of early commencement
of therapy is to be attained.





Fig. 2: Prof  Richard D’Aquilla; Northwestern University
Profile photo:
HIV Cure Researchers
The foremost name here is Gero Hütter (born
December 18, 1968), a German hematologist whose
medical team managed Timothy Ray Brown. In 2009,
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Hütter, Eckhard Thiel and others from the Charité
Hospital in Berlin, Germany, published their report in
the New England Journal of Medicine(10). This feat
earned Hütter the recognition of being the first doctor
to functionally cure the disease. This achievement has
led to an increasing number of workers searching for
methods of  curing HIV infection. Workshops pulling
together workers in the field of HIV Cure Research
are increasingly being held worldwide.
The number of HIV Cure Researchers is rapidly
increasing. A search of  PUBMED (search terms: HIV
Cure Research, unstructured search) done on the 5th
of May 2014, clearly showed a rapid increase in
numbers of Publications reporting HIV Cure Research.
The search yielded 16 publications spanning 1989 –
2010 (22 year period), and 67 publications spanning
2011- 2013 (4 year period), table 1. The first publication
was by Franchini in 198916 while the latest report was
in December 2013 by Watters17. While an unstructured
On Thursday April 24, 2014, Prof Richard D’Aquilla
of  the Feinberg School of  Medicine, Northwestern
University, Chicago (whose work on HIV Cure is at
the cutting edge of research15) coordinated such a
workshop to develop feasible HIV cure research
strategies that synergize with HIV prevention efforts.
This workshop had international presenters with
research focus on understanding how anti-retroviral
therapy started very early, after HIV infection, may
lead to sustained remission when therapy stops and
research to determine specific immune defenses that
makes this response possible. The high point of the
workshop was an address by Timothy Ray Brown
who is currently free of the virus and is off HIV
medications.
PUBMED search has limitations, the trend of this new
era is clear; HIV Cure Research will witness exponential
increase in interest and publications in the coming years.
Table 1 is a brief  compilation of  some excellent review
articles in this new focus of HIV research. The much
anticipated cure for HIV is at the Horizon; a new era
has begun and indications show that this is an era that
will end in success.
CONCLUSIONS
HIV is a global pandemic that has affected every ethnic
group in the world. The disease has remained incurable
but the focus of research into therapeutic approaches
is changing. The goal of  therapy is evolving from
control to functional and hopefully sterilizing cure. A
new era has begun. People living with the virus are
eagerly awaiting the announcement of an effective,
affordable, side-effect free, cure. This will bring an
end to the stigma associated with the infection. The
disease has led to development of international linkages
and novel methods in biomedical research. It is a
pandemic that places a demand for action on every
medical scientist in every country of the world. The
bigger picture is that every step towards finding a cure
for HIV is also a step closer to finding a cure for
other incurable diseases, especially cancer18. This Hope
must be kept alive, vigorously pursued, and adequately
funded by sitting governments and wealthy individuals
in every nation of the world.
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Fig. 3: PUBMED Publications with themes on HIV
Cure Research
Year Publication Title (citation)
2014 Early treatment during primary infection holds the key to a functional cure for HIV19
2013 Child cured of  HIV: can this be repeated?20
2013 A cure for AIDS: a matter of  timing?14
2013 Development of  hematopoietic stem cell based gene therapy for HIV-1 infection:
considerations for proof  of  concept studies and translation to standard medical practice21
2013 Will it be possible to live without antiretroviral therapy?22
Table 1: A selection of  review articles on HIV Cure Research
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